MT
Therapeutic Areas
Quanterix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LucentAD Complete | Alzheimer's Disease Detection | FDA 510(k) Submission |
| p-tau 205 & p-tau 212 Assays | Alzheimer's Disease Research | Research Use |
| Neurology Biomarker Portfolio (GFAP, Nf-L) | Traumatic Brain Injury / Neurodegeneration | Clinical Research / LDT |
Leadership Team at Quanterix
MJ
Michael J. Doyle
Chief Financial Officer
BJ
Brian J. Blaser
Chief Operating Officer
AA
Amir Ali Talasaz, Ph.D.
Chief Strategy Officer & President, Diagnostics
W(
William (Bill) R. Donnelly
Chief Commercial Officer
DC
David C. Duffy, Ph.D.
Chief Technology Officer
EK
E. Kevin Hrusovsky
Founder & Executive Chairman